Detection and time course of humoral-mediated cytotoxicity to different cell types in diabetes-prone BB/OK rats. 1991

D Schröder, and B Hehmke, and I Klöting, and S Schmidt
Department of Experimental Diabetes Research, Institute of Diabetes Gerhardt Katsch, Karlsburg, Germany.

Sera from diabetes-prone BB/OK rats were tested for humoral-mediated cytotoxicity to rat pancreatic islet cells, spleen lymphocytes and exocrine pancreatic cells using 51Cr-release assay systems. At the age of 20, 30 and 40 days all cross-sectionally studied BB/OK rats showed cytotoxicity to islet cells but only 37.5%, 25.0% and 63.3% of them exhibited anti-lymphocyte cytotoxicity, respectively. Neither the time course of cytotoxicity to islet cells nor to lymphocytes differed in BB/OK rats developing diabetes compared to animals maintaining normoglycaemia as evidenced in a follow-up study. The decrease of cytotoxicity to islet cells in vitro as observed in the time course study seems to be due to the appearance of an inhibitor of anti-islet cell cytotoxicity in serum from BB/OK rats older than 70 days. However, under conditions avoiding the influence of inhibitory components the observed time course of anti-islet cell cytotoxicity also did not permit to distinguish potential diabetic BB/OK rats from animals maintaining normoglycaemia. In contrast, long-term normoglycaemic BB/OK rats showed a peak value of cytotoxicity to rat exocrine pancreatic cells between 40 and 50 days of age only whereas animals developing diabetes more frequently displayed cytotoxicity in the prediabetic phase. Inhibitory activity against cytotoxicity to exocrine cells was not likewise detectable in BB/OK rat serum. In conclusion, except of more frequently appearing cytotoxicity to rat exocrine pancreatic cells among the investigated BB/OK rats becoming diabetic the cytotoxicity patterns to islet cells and spleen lymphocytes were not predictive for diabetes onset. Thus, humoral-mediated cytotoxicity seems to appear in BB/OK rats as a sign of immune dysregulation characteristic for this animal model at high risk for diabetes rather than in a manner related to disease manifestation.

UI MeSH Term Description Entries
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D011913 Rats, Inbred BB A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT). BB Wistar Rats,Bio-Breeding Inbred Rats,Rats, BB,BB Rat,BB Rat, Inbred,BB Rats,BB Rats, Inbred,Bio Breeding Inbred Rats,Bio-Breeding Inbred Rat,Inbred BB Rat,Inbred BB Rats,Inbred Rat, Bio-Breeding,Inbred Rats, Bio-Breeding,Rat, BB,Rat, Bio-Breeding Inbred,Rat, Inbred BB,Rats, BB Wistar,Rats, Bio-Breeding Inbred,Wistar Rats, BB
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

D Schröder, and B Hehmke, and I Klöting, and S Schmidt
January 1994, Experimental and clinical endocrinology,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
August 1987, Experimental and clinical endocrinology,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
June 2003, Autoimmunity,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
October 1989, Diabetes,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
January 2013, Genes & nutrition,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
January 1989, Autoimmunity,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
January 1999, Autoimmunity,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
October 1997, Biochemical and biophysical research communications,
D Schröder, and B Hehmke, and I Klöting, and S Schmidt
March 2002, Autoimmunity,
Copied contents to your clipboard!